Jean-Jacques Bienaimé
Mr. Bienaimé is CEO and President of Biomarin, and has over 25 years of experience in the biotechnology and pharmaceutical industries. Prior to joining Biomarin, Mr. Bienaimé was Chairman, CEO, and President of Genencor, a biotechnology company focused on industrial bioproducts and targeted cancer biotherapeutics. Genencor was acquired by Danisco in 2005. Prior to Genencor, he served as Chairman, CEO, and President of SangStat Medical Corporation, where he managed SangStat’s 25-fold revenue growth, guiding the company to profitability before its acquisition by Genzyme Corporation in 2002. Prior to SangStat, Mr. Bienaimé held several senior management positions at Rhone-Poulenc Rorer (now Sanofi-Aventis) and Genentech, where he was involved in launching Lovenox, Taxotere, and tissue plasminogen activator (t-PA). Mr. Bienaimé is a member of the board of directors of Aerogen Inc, NeurogesX Inc, and the Fox Chase Cancer Center in Philadelphia. He received an MBA from the Wharton School at the University of Pennsylvania and an undergraduate degree in economics from the Ecole Supérieure de Commerce de Paris.

 

Dr. William J. Jenkins
Dr. Jenkins has been a consultant to pharmaceutical companies, investment funds, and venture capital firms in the healthcare sector since 1999, as well as being a member of the supervisory board of several companies in this sector. From 1997 to 1999 he was Head of Clinical Development & Regulatory Affairs for Novartis Pharma AG, after having held the same position premerger at Ciba-Geigy since 1992. Dr. Jenkins oversaw the development, registration, and approval of several new drugs while at Ciba-Geigy and Novartis, including Diovan, Femara, and Simulect. Previously he was Head of Global Clinical Research at Glaxo, where he oversaw the clinical development, registration, and approval of drugs such as Zofran, Imigran, Serevent, and Fluticasone. He is currently a member of the board of directors of Acambis plc, BTG plc, Eurand NV, Evotec AG, and Monogram Biosciences Inc. Dr. Jenkins holds an MD, MSc, and MA, and is a Fellow of the Royal College of Physicians.

 

Prof. Dr. Thomas Szucs
Prof. Szucs is Chairman of the Board of Directors of BB BIOTECH and Co-Chairman at the European Center of Pharmaceutical Medicine. He is also a Professor of Pharmacology/Pharmaeconomics at the University of Milan, and Associate Professor for Medical Economics at the University of Zurich. He was formerly the Chief Medical Officer of Hirslanden Holding, the largest private hospital chain in Switzerland. Previously, he headed several institutes and groups focusing on medical economics, was a Senior Consultant at Arthur D. Little Inc, and was Head of the Department of Health Economics at F. Hoffmann-La Roche Ltd in Basel. He holds an MD degree from the University of Basel, an MBA from the University of St. Gallen, an LLM from the University of Zurich, and an MPH from Harvard University. He is also a member of the board of directors of BioXell spa and Okairos AG and of the editorial boards of several scientific journals and has published more than 140 articles, book chapters, and monographies.